These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2327180)

  • 1. Interleukin-2 activated cells from peripheral blood of patients with systemic lupus erythematosus.
    Jira M; Strejcek J; Zavadil Z; Antosova E; Rejholec V
    Z Rheumatol; 1990; 49(1):30-3. PubMed ID: 2327180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus.
    Park YW; Kee SJ; Cho YN; Lee EH; Lee HY; Kim EM; Shin MH; Park JJ; Kim TJ; Lee SS; Yoo DH; Kang HS
    Arthritis Rheum; 2009 Jun; 60(6):1753-63. PubMed ID: 19479851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-12 and IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients.
    Verma V; Sharma V; Shrivastava SK; Nadkarni JJ
    J Exp Clin Cancer Res; 2000 Sep; 19(3):367-74. PubMed ID: 11144531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
    Brooks B; Rees RC
    Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
    Provinciali M; Di Stefano G; Stronati S; Fabris N
    Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
    Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin (IL)-2 deficiency aggravates the defect of natural killer cell activity in AIDS patients.
    Zerhouni B; Sanhadji K; Kehrli L; Livrozet JM; Touraine JL
    Thymus; 1997; 24(3):147-56. PubMed ID: 9151380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of reactive oxygen species on lymphokine-activated killer cells in patients with bladder cancer.
    Wang ZP; Chen YR; Zheng RL; Lu JZ; Wang JJ
    Acta Pharmacol Sin; 2002 Mar; 23(3):257-62. PubMed ID: 11918852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of exercise-induced augmentation of lymphokine activated killer (LAK) cell activity in the horse.
    Horohov DW; Keadle TL; Pourciau SS; Littlefield-Chabaud MA; Kamerling SG; Keowen ML; French DD; Melrose PA
    Vet Immunol Immunopathol; 1996 Oct; 53(3-4):221-33. PubMed ID: 8969043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Independence of depressed lectin-dependent cell-mediated cytotoxicity from interleukin 2 production in patients with systemic lupus erythematosus.
    Perl A; González-Cabello R; Onody K; Bodó I; Gergely P
    Clin Exp Immunol; 1986 Aug; 65(2):286-92. PubMed ID: 3491706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients.
    Lauwerys BR; Garot N; Renauld JC; Houssiau FA
    Arthritis Rheum; 2000 Sep; 43(9):1976-81. PubMed ID: 11014347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
    Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.
    Kawakami Y; Custer MC; Rosenberg SA; Lotze MT
    J Immunol; 1989 May; 142(10):3452-61. PubMed ID: 2654291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperreactivity of activated B cells to B cell growth factor in patients with systemic lupus erythematosus.
    Ueda Y; Sakane T; Tsunematsu T
    J Immunol; 1989 Dec; 143(12):3988-93. PubMed ID: 2592765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responsiveness of systemic lupus erythematosus T cells to signals provided through LCA T200 (CD45) and T1 (CD5) antigens.
    Martorell J; Font J; Rojo I; Vilella R; Ingelmo M; Vives J
    Clin Exp Immunol; 1989 Nov; 78(2):172-6. PubMed ID: 12412744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.
    Green MR; Kennell AS; Larche MJ; Seifert MH; Isenberg DA; Salaman MR
    Clin Exp Immunol; 2005 Jul; 141(1):165-73. PubMed ID: 15958083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.